• 1. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 2. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 5. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Phenylpyridines

Recent Advances in the Study of 3-(4-Fluorophenyl)pyridine-2-carbonitrile (CAS: 1214340-31-4) in Chemical Biology and Pharmaceutical Research

3-(4-Fluorophenyl)pyridine-2-carbonitrile (CAS: 1214340-31-4) is a fluorinated pyridine derivative that has garnered significant attention in recent chemical biology and pharmaceutical research. This compound, characterized by its unique structural features, has been explored for its potential applications in drug discovery, particularly as a key intermediate or active pharmaceutical ingredient (API) in the development of novel therapeutics. Recent studies have highlighted its role in modulating various biological targets, including kinases and G-protein-coupled receptors (GPCRs), making it a promising candidate for further investigation.

One of the most notable advancements in the study of 3-(4-Fluorophenyl)pyridine-2-carbonitrile is its application in the synthesis of kinase inhibitors. Kinases play a critical role in cellular signaling pathways, and their dysregulation is often associated with cancer and other diseases. Researchers have successfully incorporated this compound into the scaffold of several kinase inhibitors, demonstrating its versatility in drug design. For instance, a 2023 study published in the Journal of Medicinal Chemistry reported the development of a series of potent and selective kinase inhibitors using 3-(4-Fluorophenyl)pyridine-2-carbonitrile as a core building block. The study emphasized the compound's ability to enhance binding affinity and selectivity, thereby improving the therapeutic profile of the resulting inhibitors.

In addition to its role in kinase inhibition, 3-(4-Fluorophenyl)pyridine-2-carbonitrile has also been investigated for its potential in targeting GPCRs. GPCRs are a large family of membrane proteins involved in numerous physiological processes, and they represent a major class of drug targets. A recent preprint on bioRxiv described the use of this compound in the development of allosteric modulators for specific GPCR subtypes. The researchers employed structure-activity relationship (SAR) studies to optimize the compound's interactions with the receptor, leading to improved efficacy and reduced off-target effects. These findings underscore the compound's utility in the design of next-generation GPCR-targeted therapies.

Beyond its pharmacological applications, 3-(4-Fluorophenyl)pyridine-2-carbonitrile has also been the subject of synthetic chemistry research. Advances in catalytic methods, such as palladium-catalyzed cross-coupling reactions, have enabled more efficient and scalable synthesis of this compound. A 2022 article in Organic Letters detailed a novel one-pot synthesis approach that significantly reduces the number of steps and improves yield compared to traditional methods. Such innovations are critical for facilitating the large-scale production of this compound, which is essential for both preclinical and clinical studies.

Despite these promising developments, challenges remain in the full exploitation of 3-(4-Fluorophenyl)pyridine-2-carbonitrile's potential. For example, its metabolic stability and pharmacokinetic properties require further optimization to ensure its suitability as a drug candidate. Ongoing research is focused on addressing these limitations through structural modifications and formulation strategies. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate progress in this area, paving the way for the eventual translation of this compound into clinically viable therapeutics.

In conclusion, 3-(4-Fluorophenyl)pyridine-2-carbonitrile (CAS: 1214340-31-4) represents a versatile and valuable tool in chemical biology and pharmaceutical research. Its applications in kinase inhibition, GPCR modulation, and synthetic chemistry highlight its broad utility, while ongoing studies continue to refine its properties for therapeutic use. As research in this area advances, this compound is likely to play an increasingly important role in the discovery and development of novel drugs.

• 868944-81-4(2-Pyridinecarbonitrile, 3-(2-fluorophenyl)-)
• 68164-78-3(2-Cyano-6-methyl-3-phenylpyridine)
• 39065-43-5(3-Phenylpicolinonitrile)
• 866116-05-4([4,4'-Bipyridine]-2,2'-dicarbonitrile, 3,3'-dimethyl-)
• 57420-08-3( )
• 678163-06-9(1H-PYRROLE-2-CARBONITRILE, 3-(4-FLUOROPHENYL)-4-(4-PYRIDINYL)-)
• 1214343-23-3(Pyridine, 3-(3-fluorophenyl)-2-methyl)
• 1261269-46-8(2-Pyridinecarbonitrile, 3,5-diphenyl-)
• 143425-48-3(3-(4-Methylphenyl)pyridine-2-carbonitrile)
• 914349-75-0(5-(4-Fluorophenyl)pyridine-2-carbonitrile)